Details of Disease

General Information of Disease (ID: DIS28NEL)

• Disease Name: Acute monocytic leukemia
• Synonyms: acute monoblastic/monocytic leukaemia; leukemia, acute monocytic; acute monoblastic leukaemia; acute myeloblastic leukaemia type 5; AML-M5; acute myeloblastic leukemia type 5; acute monoblastic/monocytic leukemia; acute monoblastic leukemia; monocytic leukaemia; monocytic leukemia; acute monocytic leukaemia (FAB M5b); monocytic leukemia, acute; acute monocytic leukemia, FAB M5; AML M5; acute monocytic leukemia, morphology; acute monocytic leukaemia (FAB M5B); acute monocytic leukemia (FAB M5B); acute monocytic leukemia (FAB M5b); acute monocytic leukemia, morphology (morphologic abnormality); acute monoblastic leukaemia and acute monocytic leukaemia; leukemia, monocytic, malignant; acute monoblastic leukemia and acute monocytic leukemia; acute monocytic leukaemia without mention of remission; acute monocytic leukemia; acute monocytic leukemia without mention of remission
• Definition: Acute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11).
• Disease Hierarchy:
  DIS8M755: Monocytic leukemia
  DISCSPTN: Acute myelogenous leukaemia
  DIS28NEL: Acute monocytic leukemia
• Disease Identifiers:
  MONDO ID: MONDO_0007896
  MESH ID: D007948
  UMLS CUI: C0023465
  OMIM ID: 151380
  MedGen ID: 7319
  HPO ID: HP:0004845
  Orphanet ID: 514
  SNOMED CT ID: 22331004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Daunorubicin	DMQUSBT	Approved	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 74 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCC1	TTOI92F	Limited	Altered Expression	[2]
ABCC3	TTVLG21	Limited	Biomarker	[3]
CALR	TTUZ7OA	Limited	Genetic Variation	[4]
CD19	TTW640A	Limited	Altered Expression	[5]
CD34	TTZAVYN	Limited	Biomarker	[6]
CD38	TTPURFN	Limited	Biomarker	[7]
CDK9	TT1LVF2	Limited	Biomarker	[8]
CSF3R	TTC70AJ	Limited	Genetic Variation	[9]
DCK	TTJOCE4	Limited	Biomarker	[10]
EBP	TT4VQZX	Limited	Biomarker	[11]
IDH1	TTV2A1R	Limited	Genetic Variation	[12]
IL3RA	TTENHJ0	Limited	Altered Expression	[13]
MCL1	TTL53M6	Limited	Biomarker	[14]
MDM4	TT9OUDQ	Limited	Biomarker	[15]
MLANA	TT362RB	Limited	Biomarker	[16]
MPO	TTVCZPI	Limited	Altered Expression	[17]
NCAM1	TTVXPHT	Limited	Biomarker	[18]
NPM1	TTHBS98	Limited	Biomarker	[19]
NSD1	TTTSJ3H	Limited	Biomarker	[20]
PML	TTLH9NY	Limited	Genetic Variation	[21]
PTP4A3	TT7YM8D	Limited	Biomarker	[22]
RARA	TTW38KT	Limited	Biomarker	[23]
SEPTIN6	TTAGE7U	Limited	Biomarker	[24]
RAD51	TTC0G1L	moderate	Biomarker	[25]
BCAT1	TTES57P	Strong	Altered Expression	[26]
BRIP1	TTZV7LJ	Strong	Biomarker	[25]
CBL	TT7QT13	Strong	Genetic Variation	[27]
CCR7	TT2GIDQ	Strong	Altered Expression	[28]
CD200	TT0BE68	Strong	Altered Expression	[29]
CD33	TTJVYO3	Strong	Biomarker	[30]
CD6	TTMF6KC	Strong	Genetic Variation	[31]
CD96	TT83C4X	Strong	Biomarker	[32]
CDA	TTQ12RK	Strong	Biomarker	[33]
CDK8	TTBJR4L	Strong	Altered Expression	[34]
CEBPA	TT5LWG1	Strong	Genetic Variation	[35]
CLEC12A	TT70N8V	Strong	Biomarker	[36]
CSNK1A1	TTFQEMX	Strong	Biomarker	[37]
CXCR4	TTBID49	Strong	Biomarker	[38]
DEK	TT1NMGV	Strong	Genetic Variation	[39]
EIF2AK2	TTXEZJ4	Strong	Biomarker	[40]
ELANE	TTPLTSQ	Strong	Altered Expression	[17]
FABP4	TTHWMFZ	Strong	Biomarker	[41]
FANCA	TTV5HJS	Strong	Biomarker	[25]
FANCF	TTNZKFJ	Strong	Biomarker	[25]
FCGR1A	TTZK4I3	Strong	Biomarker	[42]
FCGRT	TTKLPHO	Strong	Biomarker	[43]
FDXR	TT3W4IX	Strong	Biomarker	[2]
GLIPR1	TTEQF1O	Strong	Altered Expression	[44]
IL1RAP	TTWS50K	Strong	Biomarker	[45]
INPP5D	TTTP2Z1	Strong	Genetic Variation	[46]
KAT6A	TT6O1J0	Strong	Biomarker	[47]
KDM1A	TTNR0UQ	Strong	Biomarker	[48]
KDM5A	TTIG67W	Strong	Biomarker	[49]
LAMP2	TTULDG7	Strong	Altered Expression	[50]
LCK	TT860QF	Strong	Biomarker	[51]
LILRB2	TTHC6XU	Strong	Altered Expression	[52]
LILRB4	TTREOKA	Strong	Biomarker	[53]
LMO2	TTFX379	Strong	Altered Expression	[54]
NCR1	TTQNRJM	Strong	Biomarker	[55]
NR4A3	TTJQB49	Strong	Biomarker	[56]
PTP4A2	TT1MHKD	Strong	Altered Expression	[57]
RPS6KA1	TTIXKA4	Strong	Biomarker	[58]
RRM1	TTWP0NS	Strong	Genetic Variation	[59]
RUNX1	TTWIN3H	Strong	Genetic Variation	[60]
SIRPA	TTBRJS9	Strong	Altered Expression	[61]
SIRT6	TTUXYWF	Strong	Altered Expression	[62]
SLC12A3	TTP362L	Strong	Biomarker	[63]
SPN	TTOZAX0	Strong	Altered Expression	[64]
SYVN1	TT8XKYM	Strong	Biomarker	[65]
THPO	TTCG5PE	Strong	Biomarker	[66]
TXNIP	TTTLDZK	Strong	Biomarker	[67]
UBE2T	TT0A1R8	Strong	Biomarker	[25]
USP2	TTUEQ1W	Strong	Biomarker	[68]
VSIR	TT51SK8	Strong	Altered Expression	[69]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC27A5	DT0TQS3	Strong	Genetic Variation	[70]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CMPK1	DEMPH4I	Strong	Biomarker	[71]
CYP7A1	DEDZRQ1	Strong	Biomarker	[72]

This Disease Is Related to 172 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
BAALC	OTUZSRVF	Limited	Biomarker	[73]
BCR	OTCN76C1	Limited	Biomarker	[74]
CBFB	OTIAC6W4	Limited	Genetic Variation	[75]
CDKN2B	OTAG24N1	Limited	Biomarker	[76]
CPOX	OTIAY121	Limited	Biomarker	[11]
GATA2	OTBP2QQ2	Limited	Genetic Variation	[77]
GFI1	OT9HB9H8	Limited	Biomarker	[78]
HAVCR2	OTOL603T	Limited	Altered Expression	[79]
HOXA9	OTKNK5H0	Limited	Altered Expression	[80]
IDH2	OTTQA4PB	Limited	Biomarker	[81]
MECOM	OTP983W8	Limited	Genetic Variation	[77]
MLLT10	OTURMDV7	Limited	Genetic Variation	[82]
MLLT3	OTXH4DDG	Limited	Altered Expression	[47]
PTPA	OTRGFOI7	Limited	Genetic Variation	[83]
RUNX1T1	OT30DED5	Limited	Altered Expression	[84]
TBC1D9	OTSSCTB5	Limited	Altered Expression	[85]
TBX22	OTT1RM26	Limited	Biomarker	[11]
TESC	OTI8C76M	Limited	Biomarker	[63]
TET2	OTKKT03T	Limited	Biomarker	[27]
TSC1	OTFF4YZ7	Limited	Biomarker	[63]
TSC2	OT47LWI9	Limited	Genetic Variation	[86]
FANCM	OTNJG99Z	moderate	Biomarker	[25]
MSH3	OTD3YPVL	moderate	Altered Expression	[2]
RAD51C	OTUD6SY5	moderate	Biomarker	[25]
AADAC	OT8VACT2	Strong	Genetic Variation	[87]
ABI1	OT5H4M62	Strong	Genetic Variation	[88]
ACOT7	OT7C68YV	Strong	Altered Expression	[89]
ADGRG1	OTQBB8NT	Strong	Altered Expression	[6]
AFDN	OTTRU341	Strong	Biomarker	[90]
AKAP13	OTOZAR14	Strong	Biomarker	[91]
AMFR	OTQRX7LC	Strong	Biomarker	[92]
APOBEC3A	OTYO6F5P	Strong	Altered Expression	[93]
ARHGAP26	OTNGQU7A	Strong	Genetic Variation	[94]
ARID1B	OTILK3Q7	Strong	Biomarker	[95]
ARID3A	OTZZ4SFP	Strong	Biomarker	[95]
ASH2L	OT3HG324	Strong	Altered Expression	[96]
ASXL1	OTX931AW	Strong	Biomarker	[27]
ASXL2	OTNG4E2M	Strong	Genetic Variation	[84]
BABAM2	OTOY7FNT	Strong	Altered Expression	[97]
BCL2L10	OTYXQJ3I	Strong	Biomarker	[98]
BCL2L11	OTNQQWFJ	Strong	Biomarker	[58]
BCLAF1	OT7T8H6A	Strong	Biomarker	[99]
BCORL1	OTPTFQN5	Strong	Genetic Variation	[100]
BIRC6	OTCQJAB0	Strong	Altered Expression	[101]
BLM	OTEJOAJX	Strong	Biomarker	[25]
BRCA1	OT5BN6VH	Strong	Biomarker	[25]
BST1	OTAV5SE7	Strong	Biomarker	[102]
CAB39L	OTQEBL0W	Strong	Genetic Variation	[103]
CARTPT	OTTE4V9S	Strong	Biomarker	[104]
CBFA2T3	OTOJ10S1	Strong	Genetic Variation	[105]
CHD4	OTBDEHDP	Strong	Biomarker	[106]
CHORDC1	OT3W6F1U	Strong	Biomarker	[47]
CIRBP	OTXWTPBL	Strong	Altered Expression	[107]
CNTNAP1	OT5Y03EU	Strong	Genetic Variation	[108]
CTC1	OTRJY7QD	Strong	Biomarker	[25]
CTDSPL	OTZJ0CZK	Strong	Altered Expression	[109]
DDX18	OTKB9C3S	Strong	Biomarker	[110]
DERL3	OTRZRT6Q	Strong	Biomarker	[65]
DGUOK	OT78HUZB	Strong	Altered Expression	[111]
DUSP7	OT6Z5AHP	Strong	Altered Expression	[112]
EBF3	OTB0IWLW	Strong	Posttranslational Modification	[113]
EFS	OT06O7XL	Strong	Biomarker	[114]
EHD3	OTOKC2G5	Strong	Posttranslational Modification	[115]
EIF4B	OTE8TXA8	Strong	Biomarker	[58]
ELL	OTCBN5LF	Strong	Genetic Variation	[116]
ERCC4	OTFIOPG1	Strong	Biomarker	[25]
EVPL	OTZIAFEK	Strong	Genetic Variation	[108]
FANCB	OTMZTXB5	Strong	Biomarker	[25]
FANCC	OTTIDM3P	Strong	Biomarker	[117]
FANCD2	OTVEB5LF	Strong	Biomarker	[25]
FANCE	OTKRPBW1	Strong	Biomarker	[25]
FANCG	OT7MC8TZ	Strong	Biomarker	[25]
FANCI	OTW8E3SC	Strong	Biomarker	[25]
FANCL	OTJC7QPQ	Strong	Biomarker	[25]
FBXW4	OTEGSZOX	Strong	Genetic Variation	[87]
FIS1	OT2HL10J	Strong	Biomarker	[118]
FRYL	OTBN3XHN	Strong	Genetic Variation	[119]
GAS7	OT0M5TNY	Strong	Biomarker	[120]
GATA1	OTX1R7O1	Strong	Genetic Variation	[121]
GFI1B	OTRDW8YO	Strong	Altered Expression	[122]
GLIS2	OTOUUV1X	Strong	Altered Expression	[123]
GNL3	OTILGYO4	Strong	Altered Expression	[124]
GPHN	OTAKK1SV	Strong	Genetic Variation	[125]
HERC5	OTZ5PR39	Strong	Biomarker	[72]
HIP1	OT7AKCFQ	Strong	Altered Expression	[126]
HLA-DRB4	OTNXIHQU	Strong	Genetic Variation	[127]
HLF	OTTRK9XN	Strong	Biomarker	[128]
HOXA4	OTNVTQDT	Strong	Altered Expression	[129]
HOXB2	OTTD6HMV	Strong	Altered Expression	[130]
HOXC5	OTPQTLKZ	Strong	Altered Expression	[131]
IKBKE	OT5VYOSM	Strong	Biomarker	[132]
IKZF1	OTCW1FKL	Strong	Biomarker	[133]
IL2RG	OTRZ3OMY	Strong	Altered Expression	[134]
IRF7	OTC1A2PQ	Strong	Altered Expression	[135]
JARID2	OT14UM8H	Strong	Biomarker	[136]
KAT2A	OTN0W2SW	Strong	Biomarker	[137]
KAT7	OTUN98IC	Strong	Altered Expression	[138]
KLHL1	OTAX6SAD	Strong	Altered Expression	[85]
LCP2	OT57KE22	Strong	Biomarker	[139]
LIN28B	OTVWP0FN	Strong	Biomarker	[140]
LLGL1	OTAIQSXZ	Strong	Biomarker	[141]
MAD2L2	OT24ZO59	Strong	Biomarker	[25]
MAML2	OT1TSVAR	Strong	Biomarker	[142]
MARCKSL1	OT13J2FM	Strong	Altered Expression	[143]
MATK	OTVOJJLJ	Strong	Biomarker	[51]
MBD4	OTWR9YXE	Strong	Genetic Variation	[144]
MEIS1	OTH9DKAD	Strong	Biomarker	[145]
MLLT1	OT41UZU5	Strong	Genetic Variation	[116]
MLLT11	OTG5RVHC	Strong	Altered Expression	[146]
MLLT6	OTOC9OGX	Strong	Genetic Variation	[147]
MRPL28	OT4LUTZU	Strong	Posttranslational Modification	[148]
MT1E	OTXJKU4Y	Strong	Genetic Variation	[149]
MTSS1	OT5DTDO2	Strong	Biomarker	[150]
MVP	OTJGHJRB	Strong	Altered Expression	[85]
MYH11	OTVNVWY3	Strong	Biomarker	[151]
MYH8	OT9F350W	Strong	Biomarker	[152]
MYO1F	OTOAV4AR	Strong	Biomarker	[153]
NCOA2	OTMQFPBB	Strong	Biomarker	[154]
NCOR1	OT04XNOU	Strong	Biomarker	[155]
NCR2	OT2H13BX	Strong	Altered Expression	[156]
NECTIN2	OTIE0W6O	Strong	Biomarker	[157]
NFATC1	OT4TMERS	Strong	Biomarker	[158]
NFE2	OTLM94BI	Strong	Altered Expression	[159]
NONO	OTN36Q6U	Strong	Biomarker	[160]
NUP214	OTWEA19O	Strong	Genetic Variation	[39]
NXT1	OT0VO6AY	Strong	Posttranslational Modification	[148]
ORC5	OTFPW8DE	Strong	Genetic Variation	[161]
OSCP1	OTZ4IFGJ	Strong	Biomarker	[56]
PA2G4	OT7IG7HT	Strong	Altered Expression	[162]
PALB2	OT6DNDBG	Strong	Biomarker	[25]
PARP9	OT7K4494	Strong	Genetic Variation	[70]
PHF23	OTVF5VZC	Strong	Biomarker	[163]
PHF6	OT8DXI40	Strong	Genetic Variation	[164]
PIGN	OTHHTJKX	Strong	Altered Expression	[165]
PIR	OT8ALXHU	Strong	Altered Expression	[166]
PLS3	OTYBM4PK	Strong	Altered Expression	[167]
PMAIP1	OTXEE550	Strong	Altered Expression	[168]
POU4F1	OTMHYGWQ	Strong	Altered Expression	[169]
PPP2R2A	OT9297OG	Strong	Altered Expression	[170]
PRDM16	OT0BGA27	Strong	Genetic Variation	[171]
PRKD2	OTIFSVI8	Strong	Biomarker	[172]
PSMA7	OTPHI6ST	Strong	Biomarker	[173]
PTPRA	OTZA82J1	Strong	Biomarker	[3]
RING1	OTCWTAX0	Strong	Altered Expression	[123]
RNF2	OTFPLOIN	Strong	Altered Expression	[123]
ROBO2	OTFJ9FQW	Strong	Altered Expression	[174]
RPRM	OTNNBAS1	Strong	Posttranslational Modification	[175]
RREB1	OT62460U	Strong	Altered Expression	[176]
RTL1	OTOT33IM	Strong	Biomarker	[177]
SAMHD1	OTBCIBC7	Strong	Biomarker	[178]
SBDS	OTHDCCIB	Strong	Biomarker	[25]
SEPTIN2	OT3G33TM	Strong	Biomarker	[24]
SEPTIN9	OT1VMRFQ	Strong	Genetic Variation	[179]
SIPA1L3	OTNYFUM3	Strong	Genetic Variation	[180]
SLX4	OTF6236I	Strong	Biomarker	[25]
SMAD5	OTQNSVCQ	Strong	Genetic Variation	[181]
SMR3B	OTL5HNM8	Strong	Biomarker	[22]
SRSF2	OTVDHO6U	Strong	Biomarker	[4]
SSX2	OT2Z6RLL	Strong	Altered Expression	[182]
SUB1	OTK71JYU	Strong	Posttranslational Modification	[148]
SYCE1L	OTXU44F3	Strong	Altered Expression	[85]
SYCP3	OTKOF54H	Strong	Altered Expression	[109]
TANK	OTZSGFIK	Strong	Altered Expression	[183]
TBCE	OTGBSTKS	Strong	Biomarker	[184]
TFE3	OTM99ZWH	Strong	Genetic Variation	[185]
TIGAR	OTR7NMRJ	Strong	Biomarker	[186]
TLE1	OT50MRZ1	Strong	Biomarker	[187]
TLE4	OT4QEH6T	Strong	Biomarker	[187]
TLE5	OTEH0BFG	Strong	Biomarker	[188]
TMEM132D	OTV6I4Z0	Strong	Biomarker	[189]
TRIB2	OTHSX3MX	Strong	Biomarker	[190]
TTC4	OTAPMYXU	Strong	Biomarker	[191]

References

• [1] Daunorubicin FDA Label
• [2] The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells.Cancer Chemother Pharmacol. 2009 Jul;64(2):419-24. doi: 10.1007/s00280-009-0960-6. Epub 2009 Mar 15.
• [3] Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML).Leukemia. 2002 May;16(5):833-9. doi: 10.1038/sj.leu.2402496.
• [4] Targeted molecular characterization shows differences between primary and secondary myelofibrosis.Genes Chromosomes Cancer. 2020 Jan;59(1):30-39. doi: 10.1002/gcc.22789. Epub 2019 Sep 2.
• [5] Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.Br J Haematol. 2019 Nov;187(3):372-376. doi: 10.1111/bjh.16080. Epub 2019 Jun 27.
• [6] High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.Cancer Med. 2019 Apr;8(4):1771-1778. doi: 10.1002/cam4.2053. Epub 2019 Mar 7.
• [7] MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/-catenin pathway in acute myeloid leukemia.J Exp Clin Cancer Res. 2019 May 16;38(1):200. doi: 10.1186/s13046-019-1179-y.
• [8] The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.Oncogene. 2018 May;37(20):2687-2701. doi: 10.1038/s41388-018-0150-2. Epub 2018 Mar 1.
• [9] CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.Ann Hematol. 2019 Jul;98(7):1641-1646. doi: 10.1007/s00277-019-03699-7. Epub 2019 Apr 30.
• [10] Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.Sci Rep. 2016 Nov 3;6:36199. doi: 10.1038/srep36199.
• [11] CPX-351 (vyxeos) in AML.Leuk Lymphoma. 2020 Feb;61(2):288-297. doi: 10.1080/10428194.2019.1660970. Epub 2019 Sep 24.
• [12] In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.Leukemia. 2020 Feb;34(2):416-426. doi: 10.1038/s41375-019-0582-x. Epub 2019 Oct 4.
• [13] CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.Blood Cancer J. 2017 Jun 2;7(6):e567. doi: 10.1038/bcj.2017.52.
• [14] Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.Cell Death Dis. 2019 Dec 4;10(12):917. doi: 10.1038/s41419-019-2156-2.
• [15] MDM4 overexpressed in acute myeloid leukemia patients with complex karyotype and wild-type TP53.PLoS One. 2014 Nov 18;9(11):e113088. doi: 10.1371/journal.pone.0113088. eCollection 2014.
• [16] Expression of MDM2 and p16 in angiomyolipoma.Hum Pathol. 2018 May;75:34-40. doi: 10.1016/j.humpath.2018.01.022. Epub 2018 Feb 10.
• [17] Reduced Neutrophil Elastase Activity and Neutrophil Extracellular Traps in Pediatric Acute Myeloid Leukemia May Increase the Rate of Infections.J Pediatr Hematol Oncol. 2018 May;40(4):e248-e252. doi: 10.1097/MPH.0000000000001015.
• [18] NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.Blood. 2019 May 23;133(21):2305-2319. doi: 10.1182/blood-2018-12-889725. Epub 2019 Feb 27.
• [19] Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.Leukemia. 2019 Jul;33(7):1635-1649. doi: 10.1038/s41375-018-0368-6. Epub 2019 Jan 28.
• [20] High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.Br J Haematol. 2016 Feb;172(4):581-91. doi: 10.1111/bjh.13869. Epub 2015 Dec 18.
• [21] DNMT3A mutations in Chinese childhood acute myeloid leukemia.Medicine (Baltimore). 2017 Aug;96(31):e7620. doi: 10.1097/MD.0000000000007620.
• [22] Non-canonical activation of -catenin by PRL-3 phosphatase in acute myeloid leukemia.Oncogene. 2019 Feb;38(9):1508-1519. doi: 10.1038/s41388-018-0526-3. Epub 2018 Oct 10.
• [23] Immune evasion by oncogenic proteins of acute myeloid leukemia.Blood. 2014 Mar 6;123(10):1535-43. doi: 10.1182/blood-2013-09-526590. Epub 2014 Jan 21.
• [24] SEPT2 is a new fusion partner of MLL in acute myeloid leukemia with t(2;11)(q37;q23).Oncogene. 2006 Oct 5;25(45):6147-52. doi: 10.1038/sj.onc.1209626. Epub 2006 May 8.
• [25] Germline Genetic Predisposition to Hematologic Malignancy.J Clin Oncol. 2017 Mar 20;35(9):1018-1028. doi: 10.1200/JCO.2016.70.8644. Epub 2017 Feb 13.
• [26] BCAT1 restricts KG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.Nature. 2017 Nov 16;551(7680):384-388. doi: 10.1038/nature24294. Epub 2017 Nov 8.
• [27] Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm.Int J Hematol. 2018 Aug;108(2):213-217. doi: 10.1007/s12185-018-2419-1. Epub 2018 Feb 7.
• [28] Suppression of GPR56 expression by pyrrole-imidazole polyamide represents a novel therapeutic drug for AML with high EVI1 expression.Sci Rep. 2018 Sep 13;8(1):13741. doi: 10.1038/s41598-018-32205-8.
• [29] Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.Cancer Biomark. 2018;22(3):587-595. doi: 10.3233/CBM-181368.
• [30] Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Mnster study group.Haematologica. 2019 Jan;104(1):120-127. doi: 10.3324/haematol.2018.191841. Epub 2018 Aug 9.
• [31] The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia.Mol Cancer. 2017 Jul 19;16(1):126. doi: 10.1186/s12943-017-0692-x.
• [32] Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.PLoS One. 2012;7(8):e42426. doi: 10.1371/journal.pone.0042426. Epub 2012 Aug 3.
• [33] CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.Blood Adv. 2018 Mar 13;2(5):462-469. doi: 10.1182/bloodadvances.2017014126.
• [34] A kinase-independent role for CDK8 in BCR-ABL1(+) leukemia.Nat Commun. 2019 Oct 18;10(1):4741. doi: 10.1038/s41467-019-12656-x.
• [35] Prognostic and Clinicopathological Significance of MiR-155 in Hematologic Malignancies: A Systematic Review and Meta-analysis.J Cancer. 2019 Jan 1;10(3):654-664. doi: 10.7150/jca.28537. eCollection 2019.
• [36] Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy.Br J Haematol. 2019 Mar;184(5):769-781. doi: 10.1111/bjh.15711. Epub 2018 Dec 5.
• [37] Small Molecules Co-targeting CKI and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.Cell. 2018 Sep 20;175(1):171-185.e25. doi: 10.1016/j.cell.2018.07.045. Epub 2018 Aug 23.
• [38] Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.Immunol Invest. 2019 Jan;48(1):96-105. doi: 10.1080/08820139.2018.1497057. Epub 2018 Sep 11.
• [39] A novel variant translocation (1;9)(p22;q34) resulting in a DEK/NUP214 fusion gene in a patient with acute myeloid leukemia: A case report.Oncol Lett. 2017 Dec;14(6):7021-7024. doi: 10.3892/ol.2017.7133. Epub 2017 Oct 3.
• [40] Nuclear, not cytoplasmic, PKR maneuvers in AML.Blood. 2015 Sep 24;126(13):1523-4. doi: 10.1182/blood-2015-08-661421.
• [41] Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells.Leukemia. 2017 Jun;31(6):1434-1442. doi: 10.1038/leu.2016.349. Epub 2016 Nov 25.
• [42] Flow cytometric analysis of CD64 expression pattern and density in the diagnosis of acute promyelocytic leukemia: a multi-center study in Shanghai, China.Oncotarget. 2017 Sep 11;8(46):80625-80637. doi: 10.18632/oncotarget.20814. eCollection 2017 Oct 6.
• [43] Human GM-CSF receptor alpha-chain gene is highly polymorphic but not rearranged in AML.Leukemia. 1992 Sep;6(9):893-7.
• [44] Endoplasmic reticulum protein GliPR1 regulates G protein signaling and the cell cycle and is overexpressed in AML.Oncol Rep. 2013 Nov;30(5):2254-62. doi: 10.3892/or.2013.2716. Epub 2013 Sep 4.
• [45] IL1RAP potentiates multiple oncogenic signaling pathways in AML.J Exp Med. 2018 Jun 4;215(6):1709-1727. doi: 10.1084/jem.20180147. Epub 2018 May 17.
• [46] Nuclear accumulation of SHIP1 mutants derived from AML patients leads to increased proliferation of leukemic cells.Cell Signal. 2018 Sep;49:87-94. doi: 10.1016/j.cellsig.2018.05.006. Epub 2018 May 28.
• [47] C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.Leukemia. 2018 Mar;32(3):828-836. doi: 10.1038/leu.2017.280. Epub 2017 Sep 5.
• [48] CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML.Nat Chem Biol. 2019 May;15(5):529-539. doi: 10.1038/s41589-019-0263-0. Epub 2019 Apr 15.
• [49] Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.Leuk Res. 2018 May;68:105-111. doi: 10.1016/j.leukres.2018.02.003. Epub 2018 Feb 7.
• [50] Azacitidine resistance caused by LAMP2 deficiency: a therapeutic window for the use of autophagy inhibitors in MDS/AML patients?.Autophagy. 2019 May;15(5):927-929. doi: 10.1080/15548627.2019.1586259. Epub 2019 Mar 1.
• [51] Transcriptional memory of cells of origin overrides -catenin requirement of MLL cancer stem cells.EMBO J. 2017 Nov 2;36(21):3139-3155. doi: 10.15252/embj.201797994. Epub 2017 Oct 4.
• [52] Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.Blood. 2014 Apr 10;123(15):2412-5. doi: 10.1182/blood-2013-10-532374. Epub 2014 Mar 4.
• [53] A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML.Mol Ther. 2018 Oct 3;26(10):2487-2495. doi: 10.1016/j.ymthe.2018.08.001. Epub 2018 Aug 7.
• [54] HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias.Oncogene. 2013 Nov 28;32(48):5471-80. doi: 10.1038/onc.2013.175. Epub 2013 May 27.
• [55] NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML.Oncoimmunology. 2017 Mar 24;6(12):e1307491. doi: 10.1080/2162402X.2017.1307491. eCollection 2017.
• [56] HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML.Leukemia. 2013 Jun;27(6):1358-68. doi: 10.1038/leu.2012.366. Epub 2012 Dec 18.
• [57] PRL-2 increases Epo and IL-3 responses in hematopoietic cells.Blood Cells Mol Dis. 2010 Apr 15;44(4):209-14. doi: 10.1016/j.bcmd.2010.02.013. Epub 2010 Mar 11.
• [58] FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM.Cancers (Basel). 2019 Nov 20;11(12):1827. doi: 10.3390/cancers11121827.
• [59] Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).J Transl Med. 2018 Apr 10;16(1):90. doi: 10.1186/s12967-018-1463-1.
• [60] RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs.Blood Adv. 2019 Feb 12;3(3):320-332. doi: 10.1182/bloodadvances.2018024422.
• [61] Eutopic endometrium from patients with endometriosis modulates the expression of CD36 and SIRP- in peritoneal macrophages.J Obstet Gynaecol Res. 2019 May;45(5):1045-1057. doi: 10.1111/jog.13938. Epub 2019 Mar 6.
• [62] Strong Correlation between the Expression Levels of HDAC4 and SIRT6 in Hematological Malignancies of the Adults.Pathol Oncol Res. 2017 Jul;23(3):493-504. doi: 10.1007/s12253-016-0139-5. Epub 2016 Oct 20.
• [63] How many surgically-treated angiomyolipomas are related to tuberous sclerosis complex? Insights from a retrospective multicenter study.Minerva Urol Nefrol. 2020 Apr;72(2):200-206. doi: 10.23736/S0393-2249.19.03522-7. Epub 2019 Oct 10.
• [64] Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice.Blood Adv. 2017 Aug 18;1(19):1551-1564. doi: 10.1182/bloodadvances.2017008342. eCollection 2017 Aug 22.
• [65] A novel unbalanced whole-arm translocation der(3;10)(q10;q10) in acute monocytic leukemia.Cancer Genet Cytogenet. 2010 Jun;199(2):134-8. doi: 10.1016/j.cancergencyto.2010.02.006.
• [66] Thrombopoietin mimetics for patients with myelodysplastic syndromes.Cochrane Database Syst Rev. 2017 Sep 30;9(9):CD009883. doi: 10.1002/14651858.CD009883.pub2.
• [67] The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.Blood. 2011 Sep 8;118(10):2830-9. doi: 10.1182/blood-2010-07-294827. Epub 2011 Jul 6.
• [68] Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.Genes Chromosomes Cancer. 2019 Sep;58(9):669-672. doi: 10.1002/gcc.22751. Epub 2019 Apr 8.
• [69] VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.Oncoimmunology. 2018 Jul 11;7(9):e1469594. doi: 10.1080/2162402X.2018.1469594. eCollection 2018.
• [70] Clinical and laboratory features of adult biphenotypic acute leukemia.Asia Pac J Clin Oncol. 2013 Jun;9(2):146-54. doi: 10.1111/j.1743-7563.2012.01571.x. Epub 2012 Jul 9.
• [71] Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.J Exp Clin Cancer Res. 2017 Feb 1;36(1):22. doi: 10.1186/s13046-017-0493-5.
• [72] Construction of prognostic risk prediction model based on high-throughput sequencing expression profile data in childhood acute myeloid leukemia.Blood Cells Mol Dis. 2019 Jul;77:43-50. doi: 10.1016/j.bcmd.2019.03.008. Epub 2019 Mar 28.
• [73] The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.Blood Cancer J. 2015 Oct 2;5(10):e352. doi: 10.1038/bcj.2015.76.
• [74] Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT).Am J Hematol. 2018 Jan;93(1):31-39. doi: 10.1002/ajh.24928. Epub 2017 Oct 31.
• [75] Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.Leukemia. 2019 Aug;33(8):1923-1933. doi: 10.1038/s41375-019-0395-y. Epub 2019 Feb 6.
• [76] CDKN2B Methylation Correlates with Survival in AML Patients.Iran J Pharm Res. 2017 Fall;16(4):1600-1611.
• [77] Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):24-30. doi: 10.1016/j.clml.2019.09.615. Epub 2019 Sep 28.
• [78] LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.Leukemia. 2019 Jun;33(6):1411-1426. doi: 10.1038/s41375-018-0375-7. Epub 2019 Jan 24.
• [79] Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.J Immunother Cancer. 2019 Jul 10;7(1):175. doi: 10.1186/s40425-019-0611-3.
• [80] Aberrant Expression of HOXA5 and HOXA9 in AML.Asian Pac J Cancer Prev. 2015;16(9):3941-4. doi: 10.7314/apjcp.2015.16.9.3941.
• [81] Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCR(TM) In Patients With AML And Their Clinical Impact In Mexico City.Onco Targets Ther. 2019 Oct 1;12:8023-8031. doi: 10.2147/OTT.S219703. eCollection 2019.
• [82] PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients.Leuk Res. 2012 Nov;36(11):1365-9. doi: 10.1016/j.leukres.2012.07.008. Epub 2012 Aug 5.
• [83] Novel B55-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.Oncotarget. 2016 Sep 20;7(38):61081-61092. doi: 10.18632/oncotarget.11209.
• [84] Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.Ann Hematol. 2019 Jan;98(1):83-91. doi: 10.1007/s00277-018-3492-5. Epub 2018 Sep 24.
• [85] Lung resistance-related protein (LRP) predicts favorable therapeutic outcome in Acute Myeloid Leukemia.Sci Rep. 2019 Jan 23;9(1):378. doi: 10.1038/s41598-018-36780-8.
• [86] Two novel TSC2 mutations in renal epithelioid angiomyolipoma sensitive to everolimus.Cancer Biol Ther. 2020;21(1):4-11. doi: 10.1080/15384047.2019.1665955. Epub 2019 Oct 10.
• [87] Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG).Leuk Lymphoma. 2020 Mar;61(3):588-603. doi: 10.1080/10428194.2019.1678151. Epub 2019 Oct 29.
• [88] Is t(10;11)(p11.2;q23) involving MLL and ABI-1 genes associated with congenital acute monocytic leukemia?.Cancer Genet Cytogenet. 2002 Nov;139(1):57-9. doi: 10.1016/s0165-4608(02)00616-7.
• [89] Expression level of ACOT7 influences the prognosis in acute myeloid leukemia patients.Cancer Biomark. 2019;26(4):441-449. doi: 10.3233/CBM-182287.
• [90] MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia.Blood. 2014 Jul 10;124(2):263-72. doi: 10.1182/blood-2013-09-525741. Epub 2014 Apr 2.
• [91] Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.Leukemia. 1997 Feb;11(2):206-11. doi: 10.1038/sj.leu.2400558.
• [92] Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells.Int J Mol Med. 2015 Sep;36(3):627-32. doi: 10.3892/ijmm.2015.2267. Epub 2015 Jun 30.
• [93] Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.Cancer Res. 2017 Sep 1;77(17):4579-4588. doi: 10.1158/0008-5472.CAN-16-3394. Epub 2017 Jun 27.
• [94] MLL/GRAF fusion in an infant acute monocytic leukemia (AML M5b) with a cytogenetically cryptic ins(5;11)(q31;q23q23).Genes Chromosomes Cancer. 2004 Dec;41(4):400-4. doi: 10.1002/gcc.20097.
• [95] Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.Future Oncol. 2019 Nov;15(31):3531-3545. doi: 10.2217/fon-2019-0373. Epub 2019 Sep 13.
• [96] Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia.Leuk Lymphoma. 2017 May;58(5):1207-1218. doi: 10.1080/10428194.2016.1235272. Epub 2016 Oct 13.
• [97] High BRE expression predicts favorable outcome in adult acute myeloid leukemia, in particular among MLL-AF9-positive patients.Blood. 2011 Nov 17;118(20):5613-21. doi: 10.1182/blood-2011-06-359182. Epub 2011 Sep 21.
• [98] BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.Oncotarget. 2012 Apr;3(4):490-501. doi: 10.18632/oncotarget.481.
• [99] miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.Leukemia. 2018 Feb;32(2):573. doi: 10.1038/leu.2017.310. Epub 2017 Dec 22.
• [100] ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.Genes Chromosomes Cancer. 2017 May;56(5):382-393. doi: 10.1002/gcc.22443. Epub 2017 Feb 14.
• [101] BIRC6/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis.Eur J Haematol. 2012 Feb;88(2):118-27. doi: 10.1111/j.1600-0609.2011.01734.x. Epub 2012 Jan 4.
• [102] Targeting CD157 in AML using a novel, Fc-engineered antibody construct.Oncotarget. 2017 May 30;8(22):35707-35717. doi: 10.18632/oncotarget.16060.
• [103] Leukemia-associated gene MLAA-34 reduces arsenic trioxide-induced apoptosis in HeLa cells via activation of the Wnt/-catenin signaling pathway.PLoS One. 2017 Oct 23;12(10):e0186868. doi: 10.1371/journal.pone.0186868. eCollection 2017.
• [104] Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.Mol Ther. 2015 Jan;23(1):184-91. doi: 10.1038/mt.2014.164. Epub 2014 Sep 1.
• [105] Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML.Blood Adv. 2019 May 14;3(9):1379-1393. doi: 10.1182/bloodadvances.2018028514.
• [106] Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.Blood. 2015 Sep 17;126(12):1462-72. doi: 10.1182/blood-2015-03-631606. Epub 2015 Aug 11.
• [107] Effect of moderate hypothermia on gene expression by THP-1 cells: a DNA microarray study.Physiol Genomics. 2006 Jun 16;26(1):91-8. doi: 10.1152/physiolgenomics.00296.2005. Epub 2006 Apr 4.
• [108] Establishment of a novel human myeloid leukaemia cell line (HNT-34) with t(3;3)(q21;q26), t(9;22)(q34;q11) and the expression of EVI1 gene, P210 and P190 BCR/ABL chimaeric transcripts from a patient with AML after MDS with 3q21q26 syndrome.Br J Haematol. 1997 Aug;98(2):399-407. doi: 10.1046/j.1365-2141.1997.2143029.x.
• [109] Expression of serologically identified tumor antigens in acute leukemias.Leuk Res. 2003 Jul;27(7):655-60. doi: 10.1016/s0145-2126(02)00230-8.
• [110] Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML.Blood. 2011 Jul 28;118(4):903-15. doi: 10.1182/blood-2010-11-318022. Epub 2011 Jun 7.
• [111] Real-time quantitative PCR assays for deoxycytidine kinase, deoxyguanosine kinase and 5'-nucleotidase mRNA measurement in cell lines and in patients with leukemia.Leukemia. 2002 Mar;16(3):386-92. doi: 10.1038/sj.leu.2402388.
• [112] Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia.Cancer Lett. 2003 Sep 25;199(2):185-92. doi: 10.1016/s0304-3835(03)00352-5.
• [113] Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.J Exp Clin Cancer Res. 2015 Jan 22;34(1):4. doi: 10.1186/s13046-014-0118-1.
• [114] The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.Leukemia. 2019 Feb;33(2):348-357. doi: 10.1038/s41375-018-0227-5. Epub 2018 Aug 8.
• [115] Discovery of epigenetically silenced genes in acute myeloid leukemias.Leukemia. 2007 May;21(5):1026-34. doi: 10.1038/sj.leu.2404611. Epub 2007 Mar 1.
• [116] A New Complex Karyotype Involving a KMT2A-r Variant Three-Way Translocation in a Rare Clinical Presentation of a Pediatric Patient with Acute Myeloid Leukemia.Cytogenet Genome Res. 2019;157(4):213-219. doi: 10.1159/000499640. Epub 2019 Apr 12.
• [117] Discussing and managing hematologic germ line variants.Blood. 2016 Nov 24;128(21):2497-2503. doi: 10.1182/blood-2016-06-716704.
• [118] AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells.Cell Stem Cell. 2018 Jul 5;23(1):86-100.e6. doi: 10.1016/j.stem.2018.05.021. Epub 2018 Jun 14.
• [119] Translocation (4;11)(p12;q23) with rearrangement of FRYL and MLL in therapy-related acute myeloid leukemia.Cancer Genet Cytogenet. 2007 Sep;177(2):143-6. doi: 10.1016/j.cancergencyto.2007.05.021.
• [120] MLL/GAS7 fusion in a pediatric case of t(11;17)(q23;p13)-positive precursor B-cell acute lymphoblastic leukemia.Haematologica. 2006 Sep;91(9):1287-8.
• [121] Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies.Hematology Am Soc Hematol Educ Program. 2015;2015:507-13. doi: 10.1182/asheducation-2015.1.507.
• [122] Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia.Int J Hematol. 2009 May;89(4):422-430. doi: 10.1007/s12185-009-0286-5. Epub 2009 Apr 10.
• [123] Ring1A and Ring1B inhibit expression of Glis2 to maintain murine MOZ-TIF2 AML stem cells.Blood. 2018 Apr 19;131(16):1833-1845. doi: 10.1182/blood-2017-05-787226. Epub 2018 Jan 25.
• [124] Transcript level of nucleostemin in newly diagnosed acute myeloid leukemia patients.Leuk Res. 2013 Dec;37(12):1636-41. doi: 10.1016/j.leukres.2013.09.023. Epub 2013 Sep 29.
• [125] t(11;14)(q23;q24) generates an MLL-human gephyrin fusion gene along with a de facto truncated MLL in acute monoblastic leukemia.Cancer Res. 2001 Mar 15;61(6):2665-9.
• [126] Prognostic significance of huntingtin interacting protein 1 expression on patients with acute myeloid leukemia.Sci Rep. 2017 Apr 28;7:45960. doi: 10.1038/srep45960.
• [127] HLA class II allele and haplotype frequencies in Iranian patients with leukemia.Iran J Allergy Asthma Immunol. 2007 Sep;6(3):137-42.
• [128] Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML.Blood. 2019 Jul 18;134(3):263-276. doi: 10.1182/blood.2018862383. Epub 2019 May 10.
• [129] The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML.Eur J Haematol. 2009 Nov;83(5):439-48. doi: 10.1111/j.1600-0609.2009.01309.x. Epub 2009 Jun 25.
• [130] Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.Leukemia. 2007 Sep;21(9):2000-9. doi: 10.1038/sj.leu.2404808. Epub 2007 Jun 28.
• [131] Differentiation and cell-type-restricted expression of HOXC4, HOXC5 and HOXC6 in myeloid leukemias and normal myeloid cells.Leukemia. 1998 Nov;12(11):1724-32. doi: 10.1038/sj.leu.2401106.
• [132] The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.Blood Adv. 2018 Dec 11;2(23):3428-3442. doi: 10.1182/bloodadvances.2018016733.
• [133] High frequency of Ikaros isoform 6 expression in acute myelomonocytic and monocytic leukemias: implications for up-regulation of the antiapoptotic protein Bcl-XL in leukemogenesis.Blood. 2002 Feb 15;99(4):1350-5. doi: 10.1182/blood.v99.4.1350.
• [134] Potential to target dysregulated interleukin-2 receptor expression in canine lymphoid and hematopoietic malignancies as a model for human cancer.J Immunother. 2002 Jan-Feb;25(1):36-45. doi: 10.1097/00002371-200201000-00004.
• [135] Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.Cell Death Dis. 2014 Dec 4;5(12):e1557. doi: 10.1038/cddis.2014.502.
• [136] JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression.Int J Hematol. 2015 Jul;102(1):76-85. doi: 10.1007/s12185-015-1797-x. Epub 2015 May 5.
• [137] The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.Leukemia. 2019 Nov;33(11):2628-2639. doi: 10.1038/s41375-019-0581-y. Epub 2019 Oct 1.
• [138] MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML.Exp Hematol. 2015 Sep;43(9):794-802.e4. doi: 10.1016/j.exphem.2015.05.010. Epub 2015 Jun 11.
• [139] Retinoic acid and 6-formylindolo(3,2-b)carbazole (FICZ) combination therapy reveals putative targets for enhancing response in non-APL AML.Leuk Lymphoma. 2019 Jul;60(7):1697-1708. doi: 10.1080/10428194.2018.1543880. Epub 2018 Dec 20.
• [140] LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML.Mol Cancer Res. 2017 Mar;15(3):294-303. doi: 10.1158/1541-7786.MCR-16-0275-T. Epub 2016 Dec 23.
• [141] The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML.J Exp Med. 2013 Jan 14;210(1):15-22. doi: 10.1084/jem.20120596. Epub 2012 Dec 31.
• [142] Identification of a novel fusion gene MLL-MAML2 in secondary acute myelogenous leukemia and myelodysplastic syndrome with inv(11)(q21q23).Genes Chromosomes Cancer. 2007 Sep;46(9):813-9. doi: 10.1002/gcc.20467.
• [143] Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.Clin Cancer Res. 1997 Aug;3(8):1419-25.
• [144] MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML.Blood. 2018 Oct 4;132(14):1526-1534. doi: 10.1182/blood-2018-05-852566. Epub 2018 Jul 26.
• [145] Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML.Cell Stem Cell. 2012 Feb 3;10(2):210-7. doi: 10.1016/j.stem.2012.01.004.
• [146] Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia.Blood. 2004 Nov 15;104(10):3058-63. doi: 10.1182/blood-2003-12-4347. Epub 2004 Jun 24.
• [147] Identification of a chromosomal breakpoint and detection of a novel form of an MLL-AF17 fusion transcript in acute monocytic leukemia with t(11;17)(q23;q21).Int J Hematol. 2005 Jul;82(1):38-41. doi: 10.1532/IJH97.05025.
• [148] KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients.Leuk Res. 2001 Oct;25(10):917-25. doi: 10.1016/s0145-2126(01)00053-4.
• [149] Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.Clin Cancer Res. 2016 Feb 15;22(4):868-76. doi: 10.1158/1078-0432.CCR-15-0481. Epub 2015 Oct 12.
• [150] Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia.PLoS One. 2015 May 21;10(5):e0125783. doi: 10.1371/journal.pone.0125783. eCollection 2015.
• [151] Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.Leukemia. 2007 Apr;21(4):725-31. doi: 10.1038/sj.leu.2404531. Epub 2007 Feb 8.
• [152] Truncation of MYH8 tail in AML: a novel prognostic marker with increase cell migration and epithelial-mesenchymal transition utilizing RAF/MAPK pathway.Carcinogenesis. 2020 Jul 10;41(6):817-827. doi: 10.1093/carcin/bgz146.
• [153] The MYO1F, unconventional myosin type 1F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22.Oncogene. 2005 Aug 4;24(33):5191-7. doi: 10.1038/sj.onc.1208711.
• [154] Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13).Cancer Genet Cytogenet. 1999 Aug;113(1):70-2. doi: 10.1016/s0165-4608(99)00007-2.
• [155] Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.BMC Genomics. 2015 Apr 17;16(1):309. doi: 10.1186/s12864-015-1445-0.
• [156] Survival in acute myeloid leukemia is associated with NKp44 splice variants.Oncotarget. 2016 May 31;7(22):32933-45. doi: 10.18632/oncotarget.8782.
• [157] Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.Oncogene. 2018 Sep;37(39):5269-5280. doi: 10.1038/s41388-018-0288-y. Epub 2018 May 31.
• [158] Nuclear factor of activated T-cells, NFATC1, governs FLT3(ITD)-driven hematopoietic stem cell transformation and a poor prognosis in AML.J Hematol Oncol. 2019 Jul 8;12(1):72. doi: 10.1186/s13045-019-0765-y.
• [159] Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.Blood. 2019 Apr 18;133(16):1766-1777. doi: 10.1182/blood-2018-09-875047. Epub 2019 Feb 12.
• [160] Knockdown of p54nrb inhibits migration, invasion and TNF- release of human acute monocytic leukemia THP1 cells.Oncol Rep. 2016 Jun;35(6):3742-8. doi: 10.3892/or.2016.4756. Epub 2016 Apr 20.
• [161] Mutation analysis of the origin recognition complex subunit 5 (ORC5L) gene in adult patients with myeloid leukemias exhibiting deletions of chromosome band 7q22.Hum Genet. 2001 Apr;108(4):304-9. doi: 10.1007/s004390100498.
• [162] Expression and Role of the ErbB3-Binding Protein 1 in Acute Myelogenous Leukemic Cells.Clin Cancer Res. 2016 Jul 1;22(13):3320-7. doi: 10.1158/1078-0432.CCR-15-2282. Epub 2016 Jan 26.
• [163] A cryptic translocation leading to NUP98-PHF23 fusion in AML.Best Pract Res Clin Haematol. 2016 Dec;29(4):320-323. doi: 10.1016/j.beha.2016.10.002. Epub 2016 Oct 18.
• [164] Somatic mutation of PHF6 gene in T-cell acute lymphoblatic leukemia, acute myelogenous leukemia and hepatocellular carcinoma.Acta Oncol. 2012 Jan;51(1):107-11. doi: 10.3109/0284186X.2011.592148. Epub 2011 Jul 8.
• [165] PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features.Oncotarget. 2017 May 2;8(18):29887-29905. doi: 10.18632/oncotarget.15136.
• [166] Pirin downregulation is a feature of AML and leads to impairment of terminal myeloid differentiation.Leukemia. 2010 Feb;24(2):429-37. doi: 10.1038/leu.2009.247. Epub 2009 Dec 10.
• [167] The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia.Cancers (Basel). 2019 Oct 26;11(11):1663. doi: 10.3390/cancers11111663.
• [168] APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.Eur J Haematol. 2011 Mar;86(3):206-15. doi: 10.1111/j.1600-0609.2010.01557.x. Epub 2011 Jan 11.
• [169] POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature.Leukemia. 2010 May;24(5):950-7. doi: 10.1038/leu.2010.61. Epub 2010 Apr 8.
• [170] The protein phosphatase 2A regulatory subunit B55 is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.Biochim Biophys Acta. 2014 Sep;1843(9):1969-77. doi: 10.1016/j.bbamcr.2014.05.006. Epub 2014 May 21.
• [171] A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation.Blood. 2003 Nov 1;102(9):3323-32. doi: 10.1182/blood-2002-12-3944. Epub 2003 Jun 19.
• [172] PRKD2 Promotes Progression and Chemoresistance of AML via Regulating Notch1 Pathway.Onco Targets Ther. 2019 Dec 12;12:10931-10941. doi: 10.2147/OTT.S233234. eCollection 2019.
• [173] Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.Cancer Res. 2020 Feb 1;80(3):458-470. doi: 10.1158/0008-5472.CAN-18-2932. Epub 2019 Nov 29.
• [174] The Expression of the SLIT-ROBO Family in Adult Patients with Acute Myeloid Leukemia.Arch Immunol Ther Exp (Warsz). 2019 Apr;67(2):109-123. doi: 10.1007/s00005-019-00535-8. Epub 2019 Feb 28.
• [175] tp53-dependent G2 arrest mediator candidate gene, Reprimo, is down-regulated by promoter hypermethylation in pediatric acute myeloid leukemia.Leuk Lymphoma. 2015;56(10):2931-44. doi: 10.3109/10428194.2015.1011157. Epub 2015 Feb 24.
• [176] RAS-Responsive Element-Binding Protein 1 Blocks the Granulocytic Differentiation of Myeloid Leukemia Cells.Oncol Res. 2019 Jul 12;27(7):809-818. doi: 10.3727/096504018X15451301487729. Epub 2019 Apr 8.
• [177] Immunohistochemical and reverse transcription-polymerase chain reaction expression analysis of tyrosinase and microphthalmia-associated transcription factor in angiomyolipomas.Appl Immunohistochem Mol Morphol. 2001 Mar;9(1):29-34.
• [178] Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.Nat Commun. 2019 Aug 2;10(1):3475. doi: 10.1038/s41467-019-11413-4.
• [179] A variant-type MLL/SEPT9 fusion transcript in adult de novo acute monocytic leukemia (M5b) with t(11;17)(q23;q25).Int J Hematol. 2008 Sep;88(2):192-196. doi: 10.1007/s12185-008-0133-0. Epub 2008 Jul 19.
• [180] Dissecting TSC2-mutated renal and hepatic angiomyolipomas in an individual with ARID1B-associated intellectual disability.BMC Cancer. 2019 May 10;19(1):435. doi: 10.1186/s12885-019-5633-1.
• [181] Inhibition of Smad5 in human hematopoietic progenitors blocks erythroid differentiation induced by BMP4.Blood Cells Mol Dis. 2002 Mar-Apr;28(2):221-33. doi: 10.1006/bcmd.2002.0487.
• [182] Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.Int J Cancer. 2019 Oct 15;145(8):2201-2208. doi: 10.1002/ijc.32028. Epub 2019 Jan 11.
• [183] Characterization of ZC3H15 as a potential TRAF-2-interacting protein implicated in the NFB pathway and overexpressed in AML.Int J Oncol. 2013 Jul;43(1):246-54. doi: 10.3892/ijo.2013.1924. Epub 2013 Apr 29.
• [184] The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission.Blood. 2012 Jun 7;119(23):5584-90. doi: 10.1182/blood-2011-11-389809. Epub 2012 Apr 24.
• [185] Hepatic angiomyolipomas may overexpress TFE3, but have no relevant genetic alterations.Hum Pathol. 2017 Mar;61:41-48. doi: 10.1016/j.humpath.2016.11.003. Epub 2016 Nov 16.
• [186] TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia.J Hematol Oncol. 2016 Nov 25;9(1):128. doi: 10.1186/s13045-016-0360-4.
• [187] Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival.Blood. 2008 Apr 15;111(8):4338-47. doi: 10.1182/blood-2007-07-103291. Epub 2008 Feb 7.
• [188] AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein.Blood. 2011 Apr 21;117(16):4328-37. doi: 10.1182/blood-2009-09-242545. Epub 2011 Jan 18.
• [189] The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.Cytotherapy. 2012 Jan;14(1):91-103. doi: 10.3109/14653249.2011.613931. Epub 2011 Oct 6.
• [190] Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells.Sci Signal. 2018 Sep 25;11(549):eaat7951. doi: 10.1126/scisignal.aat7951.
• [191] The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study.Pediatr Blood Cancer. 2010 Sep;55(3):414-20. doi: 10.1002/pbc.22511.